A Houston compounding pharmacy has pulled thousands of prefilled syringes and IV bags of ketamine, fentanyl and phenylephrine from circulation after federal inspectors said its sterile drug operations were not up to required manufacturing standards. Hospitals and surgery centers that lean on outsourced sterile meds are now combing through their stocks to see whether they were using any of the affected lots.
What was recalled
The voluntary recall involves multiple sterile injectable products made by Wells Pharma of Houston LLC. That includes ketamine hydrochloride 50 mg/mL prefilled syringes and several fentanyl formulations supplied in IV bags and syringes. Reported counts include about 4,975 ketamine syringes, roughly 2,940 250 mL fentanyl (2,500 mcg/250 mL) bags, about 4,030 100 mL fentanyl (1,000 mcg/100 mL) bags, 50 fentanyl 25 mL syringes (1,250 mcg/25 mL) and more than 13,000 250 mL phenylephrine bags across the affected lots. Federal records list the move as a Class II recall, according to PIX11.
Why regulators moved
Federal regulators say the concern is about how the drugs were made, not what is in them. The issue centers on compliance with current good manufacturing practice, or CGMP, the quality framework that covers the design, monitoring and control of drug manufacturing and facilities. The FDA notes that when those systems slip, it can open the door to contamination, wrong doses or other quality problems.
Inspectors recently visited Wells Pharma and later issued a warning letter following a 2025 inspection that cited shortcomings in the company’s quality control and labeling practices, per an FDA warning letter.
Company response and distribution
Wells Pharma’s own product listings include prefilled ketamine syringes and various fentanyl and phenylephrine preparations that line up with the items now under recall. So far, the company has not offered detailed public comment, PIX11 reports. Its website instead tells hospital partners and customers to reach out to their account representatives for instructions on how to return or dispose of affected products. Wells Pharma markets these prefilled syringes and IV admixtures primarily to acute care hospitals and surgical centers.
What hospitals and patients should do
Clinics, pharmacies and health systems that buy sterile drugs from Wells Pharma are being urged to verify lot numbers against recall notices, quarantine anything that matches and follow their supplier’s directions for returning or destroying the products. Patients who think they might have received one of the recalled drugs during a procedure and who are experiencing unusual symptoms should contact their healthcare provider. Adverse reactions can be reported to the FDA’s MedWatch program…